Project Grant R44AR087173
Award Date 8/26/26
Completion Date 7/31/27
Dollars Obligated $306K
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98122, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Virtici LLC $300,222 on August 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to commercialize VTC-L35, an orally administered, immune-modulating probiotic therapy for rheumatoid arthritis. The project targets long-term disease remission in rheumatoid arthritis patients by developing an oral immunotherapeutic that regulates auto-antigen-specific regulatory T cells and B cells to produce...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Novomedix LLC $314,362 on September 22, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop and commercialize a novel therapy for arthrofibrosis using small-molecule inhibitors of interleukin-11. The project aims to develop Novomedix small-molecule anti-inflammatory and antifibrotic drug candidates (NMX) for local application to reduce and potentially reverse...
- Navega Therapeutics, Inc. received a $297,327 Project Grant Award dated September 18, 2025, from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award supports the reformulation and development of NT-Z001, an epigenetic gene therapy designed to treat persistent pain in rheumatoid arthritis (RA) patients who remain symptomatic despite disease-modifying antirheumatic drug...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The General Hospital Corporation (Massachusetts General Hospital) $165,240 on June 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds research applying systems immunology approaches to characterize regulatory T cell (Treg) dysfunction in lupus and across multiple autoimmune conditions. The research leverages an existing integrated dataset of 3.5 million...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $676,210 to The Washington University on August 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The recipient will conduct research into DNMT3A as an epigenetic transcriptional therapeutic target in femoroacetabular impingement (FAI) progression to osteoarthritis. FAI is a pre-arthritic hip condition affecting individuals aged 20 to 40; standard surgical treatment...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Rochester $342,125 on May 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the role of telocytes in the synovial lymphatic system and their contribution to rheumatoid arthritis pathophysiology. The recipient will conduct two specific research aims over the 24-month performance period (May 1, 2026 through April 30, 2028) at the University...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded New York University School of Medicine $396,206 on September 1, 2026, to develop and validate a radiogenomic virtual biopsy approach for femoroacetabular impingement (FAI) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The project tests feasibility of linking routine magnetic resonance imaging features to bone gene expression patterns in FAI patients to enable noninvasive...
- The National Institute of Allergy and Infectious Diseases awarded the University of Florida $607,599 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a hybrid biomaterial immunotherapy system for rheumatoid arthritis. The funded work centers on engineering and testing REGVAK, a novel hybrid polymeric microparticle–lipid nanoparticle system designed to address the root cause of rheumatoid arthritis by targeting dendritic cell activation...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $421,040 to the University of Texas Health Science Center at Houston on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to support an ancillary research effort investigating mechanisms of response to CD19-redirected plurireceptor natural killer cells in systemic sclerosis and systemic lupus erythematosus. The recipient is conducting an...
- The National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded New York University School of Medicine $409,311.92 under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) from April 5, 2021 to January 25, 2022. The project grant funding supports research into the role of T follicular helper (TFH) cells in the pathogenesis of dermatomyositis, a severe inflammatory myopathy. Specifically, the award will fund studies to...